Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinib
Alexandros Rampotas, Luke Carter‐Brzezinski, Tim C. P. Somervaille, James Forryan, Fotios Panitsas, Claire Harrison, Ruth Witherall, Andrew J. Innes, Louise Wallis, Naumann M. Butt, Bethan Psaila, Adam J. Mead, Matthew Carter, Anna L. Godfrey, Heather Laing, Mamta Garg, Sebastian Francis, Joanne Ewing, Chun Huat Teh, Hannah Bibi Cowen, Peter Dyer, Conall McConville, Frances Wadelin, Ali Sahra, Andrew McGregor, Elizabeth Kulakov, Donal P. McLornan, Jonathan Lambert
Abstract
ABSTRACT: Nonmelanoma skin cancers (NMSCs) in ruxolitinib-treated patients with myeloproliferative neoplasms behave aggressively, with adverse features and high recurrence. In our cohort, mortality from metastatic NMSC exceeded that from myelofibrosis. Vigilant skin assessment, counseling on NMSC risks, and prospective ruxolitinib-NMSC studies are crucial.